Form 4: CG Oncology's Chief Medical Officer, Vijay Kasturi, Reports Stock Option Grant

Vijay Kasturi, Chief Medical Officer of CG Oncology, reports the acquisition of stock options for 132,600 shares of common stock.

Summary

• On October 4, 2024, Vijay Kasturi, the Chief Medical Officer of CG Oncology, Inc., was granted stock options to purchase 132,600 shares of the company's common stock.
• The exercise price of these options is $36.63 per share.
• The options vest monthly over a four-year period, commencing on October 4, 2024, contingent upon continuous service to the Issuer.
• The options expire on October 3, 2034.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally viewed as a positive sign of aligning management incentives with shareholder value. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates